Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA. - Test2 - elhamkhani - TriplyDB

Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA.

Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA.

http://www.wikidata.org/entity/Q34204047

about

Immune correlates of vaccine protection against HIV-1 acquisition A global approach to HIV-1 vaccine development Human Anti-V3 HIV-1 Monoclonal Antibodies Encoded by the VH5-51/VL Lambda Genes Define a Conserved Antigenic Structure Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals The V1V2 Region of HIV-1 gp120 Forms a Five-Stranded Beta Barrel.An Enhanced Synthetic Multiclade DNA Prime Induces Improved Cross-Clade-Reactive Functional Antibodies when Combined with an Adjuvanted Protein Boost in Nonhuman Primates.Controlling the HIV/AIDS epidemic: current status and global challenges Superinfection by discordant subtypes of HIV-1 does not enhance the neutralizing antibody response against autologous virus.Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.Envelope variants circulating as initial neutralization breadth developed in two HIV-infected subjects stimulate multiclade neutralizing antibodies in rabbits.Pre-clinical development of a recombinant, replication-competent adenovirus serotype 4 vector vaccine expressing HIV-1 envelope 1086 clade C.Computational prediction of neutralization epitopes targeted by human anti-V3 HIV monoclonal antibodies Cholera toxin B: one subunit with many pharmaceutical applications.A broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site.A critical question for HIV vaccine development: which antibodies to induce?Motif-optimized subtype A HIV envelope-based DNA vaccines rapidly elicit neutralizing antibodies when delivered sequentially.Production and characterization of human anti-V3 monoclonal antibodies from the cells of HIV-1 infected Indian donors.Antigenicity and Immunogenicity in HIV-1 Antibody-Based Vaccine Design Induction of neutralizing antibodies in rhesus macaques using V3 mimotope peptides.Cross-neutralizing activity of human anti-V3 monoclonal antibodies derived from non-B clade HIV-1 infected individuals Elicitation of broadly reactive antibodies against glycan-modulated neutralizing V3 epitopes of HIV-1 by immune complex vaccines.Rationally Designed Immunogens Targeting HIV-1 gp120 V1V2 Induce Distinct Conformation-Specific Antibody Responses in Rabbits.Improvement of antibody responses by HIV envelope DNA and protein co-immunization.Prospects for an HIV vaccine: leading B cells down the right path.Neutralizing antibodies and control of HIV: moves and countermoves.Basic research in HIV vaccinology is hampered by reductionist thinking.Immune System Regulation in the Induction of Broadly Neutralizing HIV-1 Antibodies.Envelope Glycoprotein Trimers as HIV-1 Vaccine Immunogens Vaccine focusing to cross-subtype HIV-1 gp120 variable loop epitopes.Functional Antibody Response Against V1V2 and V3 of HIV gp120 in the VAX003 and VAX004 Vaccine Trials.Neutralization tiers of HIV-1.Neutralizing Antibody Responses following Long-Term Vaccination with HIV-1 Env gp140 in Guinea Pigs.

P2860

Q26778573-0017D234-4F3E-4745-8A5E-1152622794A2 Q27024614-62286FC8-79EF-4527-92B2-3A7326BCCB2C Q27676155-2F00EBD3-90FE-4EDB-B311-75698B5BB34D Q27677941-FC8EA6FE-81E5-4606-B258-3F017A0D9E06 Q30152923-B258A2DB-9B9F-4FF5-8A14-5EE79DB6B238 Q30375785-E07144D3-40C1-4E43-BD1A-43E0E89BC5C9 Q30420558-82435BD1-C3EF-47AF-BE14-DC26E6198006 Q34312037-B6F1CD69-382C-43B8-AD88-CD034A90AAE7 Q34540352-CC340F32-911C-41C7-AFEB-91B90F350AF1 Q34594513-E733A308-9E25-4764-BE7B-5C43D7A4C3AB Q35061529-561284B3-5E16-47EC-AFF5-150DD05E94C0 Q35108505-03493EBF-02F1-4C35-BFAD-978A57EC5ACC Q35232735-371DA778-C53B-4180-BD02-7C03947DFE51 Q35706462-96068426-4274-45C0-AB9F-D62D79D25BF5 Q35783015-1897E3CE-249C-40A3-A94B-5264E3642AE8 Q36249053-C48FCCB3-1664-425A-968F-DEF0DE85C56A Q36384117-6F96BDCC-3C9A-4129-B4EF-D2CEEB11E304 Q36447540-E70319D7-9E69-4B03-9058-9D595763683A Q36920319-1F9D7072-ABB5-4D64-AD6B-2308F484BEEF Q37130745-D18AC3FF-A6C4-4503-A433-EB31371C7F62 Q37419234-8173A051-B503-4F7E-B4AE-502AC3697212 Q37448281-2C957C83-3CFC-4F35-A061-0763879966A6 Q37588371-19D2A817-8310-40DB-8A25-4F8E8492E043 Q37964482-535A10D8-C5DA-4601-81DF-956EDCD0D792 Q37971867-C1DAE810-42C9-450B-9D9B-5F8DB4281C78 Q38025633-DF67D0D6-C497-4C76-B44B-66EA2F159412 Q38220506-E161DD54-53CE-4FCE-9488-D67007563ECD Q38581943-D5C1BFF6-57DB-4BC8-8F1F-01EBAB2ACFAD Q42204816-87150D30-2D63-4225-932B-A0B177730C3B Q47555452-98179DB7-2938-4F15-B922-9DE4EE8421EC Q47562235-AE915892-BDA9-48D0-AB60-A51CD8FBF081 Q53693698-56F6F07D-78AE-4A78-B6A6-1870DD5E0775

P2860

Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA.

http://www.wikidata.org/entity/Q34204047

description

2011 nî lūn-bûn

@nan

2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Cross-clade HIV-1 neutralizing ...... lowing priming with gp120 DNA.

@ast

Cross-clade HIV-1 neutralizing ...... lowing priming with gp120 DNA.

@en

Cross-clade HIV-1 neutralizing ...... lowing priming with gp120 DNA.

@nl

type

label

Cross-clade HIV-1 neutralizing ...... lowing priming with gp120 DNA.

@ast

Cross-clade HIV-1 neutralizing ...... lowing priming with gp120 DNA.

@en

Cross-clade HIV-1 neutralizing ...... lowing priming with gp120 DNA.

@nl

prefLabel

Cross-clade HIV-1 neutralizing ...... lowing priming with gp120 DNA.

@ast

Cross-clade HIV-1 neutralizing ...... lowing priming with gp120 DNA.

@en

Cross-clade HIV-1 neutralizing ...... lowing priming with gp120 DNA.

@nl

P1433

Q34204047-996409BB-2374-4A28-95AD-A47102442EC2

P1476

Q34204047-3F707D8F-DAA6-4A42-9FEA-2BF46683B8A9

P2093

Q34204047-202616D0-32D5-4ED5-B5F7-04C61B4A1472

Q34204047-618DC323-976D-4821-860D-B78AA5418F4B

Q34204047-707524AB-5934-4394-B17E-9DB4F53DD835

Q34204047-759CC9E4-10B7-4751-BE6E-FCDBE04ABDBA

Q34204047-AD8BFB64-F7AF-4FB4-A89B-CEF8004AB79F

Q34204047-BA248FA5-67B7-41DC-8AA0-0ACB2CD35D16

Q34204047-D8B5D5EA-F675-463F-814A-4CC8A878562A

Q34204047-E659F035-3EB8-4964-B83F-75FE0761D685

Q34204047-E9CE8213-5D51-4953-B755-32384B0EA464

P2860

Q34204047-03399EEC-5827-4EE9-832E-CE52B252D7A0

Q34204047-0529452F-CF78-452F-9FAB-0F3FA995B561

Q34204047-08137B70-615C-4BC3-91CF-E775A8671908

Q34204047-0C915667-B1F9-4E40-9D75-B926567D3009

Q34204047-128AFE13-DA07-4151-BA4F-130E6DA462F4

Q34204047-1552152A-609F-4DD1-92A6-71345525E96D

Q34204047-190E20BA-002F-4AE4-AB12-89BAAEEEC386

Q34204047-1A39C68B-B8A6-425E-8F17-4B34FD67D50B

Q34204047-1CD25D00-1607-4DD8-8707-D5A95D710B6A

Q34204047-1D46AC47-A133-4E62-84A7-5CAB025F7D4A

P304

Q34204047-473E20A9-3234-4BAE-A191-2EE29F27B3A0

P31

Q34204047-CB48131B-50B4-408A-AC33-CA6EE60ABB56

P356

Q34204047-F9B55597-8E75-4CD8-A170-685C68B3BFA6

P407

Q34204047-935F5ACF-3849-4928-AA49-DB4C972F87BC

P433

Q34204047-CA9AF6BE-33B9-4C7B-B846-66E8B0B6DAE1

P478

Q34204047-23D9CA9E-B8BE-4035-AB69-04C1C19C1063

P50

Q34204047-053ED380-DBC5-46E8-8A1B-FADC6CD87300

P577

Q34204047-E3F5CF34-B312-4647-9577-E3F577A957A8

P5875

Q34204047-F4E3605B-AD5C-4B32-8112-125B6A20C5BF

P698

Q34204047-B111D07A-B20B-4C5B-81D6-9C9E85FD9615

P921

Q34204047-591999DE-4584-4A26-A847-5A6F7C8857C7

P932

Q34204047-57B378F9-2DF1-4A89-BE63-842B38A4DFBC

P356

P1433

Journal of Virology

P1476

Cross-clade HIV-1 neutralizing ...... llowing priming with gp120 DNA

@en

P2093

Arthur Nádas

http://www.w3.org/2001/XMLSchema#string

Maxim Totrov

http://www.w3.org/2001/XMLSchema#string

Michael S Seaman

http://www.w3.org/2001/XMLSchema#string

Sandra Cohen

http://www.w3.org/2001/XMLSchema#string

Shan Lu

http://www.w3.org/2001/XMLSchema#string

Shixia Wang

http://www.w3.org/2001/XMLSchema#string

Susan Zolla-Pazner

http://www.w3.org/2001/XMLSchema#string

Timothy Cardozo

http://www.w3.org/2001/XMLSchema#string

Xunqing Jiang

http://www.w3.org/2001/XMLSchema#string

P2860

Additive Effects Characterize the Interaction of Antibodies Involved in Neutralization of the Primary Dualtropic Human Immunodeficiency Virus Type 1 Isolate 89.6

Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D

Structure determination of an anti-HIV-1 Fab 447-52D–peptide complex from an epitaxially twinned data set

Structural Basis of the Cross-Reactivity of Genetically Related Human Anti-HIV-1 mAbs: Implications for Design of V3-Based Immunogens

Conserved structural elements in the V3 crown of HIV-1 gp120

Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope

Elicitation of structure-specific antibodies by epitope scaffolds

Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein

Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial

Comparative immunogenicity of HIV-1 clade C envelope proteins for prime/boost studies

P304

9887-9898

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.05086-11

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

85

http://www.w3.org/2001/XMLSchema#string

P50

Xiang-Peng Kong

P577

2011-07-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51526898

http://www.w3.org/2001/XMLSchema#string

P698

21795338

http://www.w3.org/2001/XMLSchema#string

P921

P932

3196418

http://www.w3.org/2001/XMLSchema#string